Granules India Limited has completed the full acquisition of Senn Chemicals AG, a Swiss company specialising in peptide development and manufacturing. This move is part of Granules’ plan to grow in the field of science and innovation, especially in peptide-based medicines.
This acquisition will strengthen Granules’ capabilities in the peptide therapeutics sector and CDMO (Contract Development and Manufacturing Organisation) services. It will help the company develop new drugs like GLP-1 receptor agonists used for treating diabetes and obesity. Both companies have already started working together on product development, with plans for a wider range of peptide-based drugs.
Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India, stated, “The acquisition of Senn Chemicals AG marks a pivotal step in Granules’ strategic evolution into a science- and innovation-led organisation. By entering the rapidly growing peptide therapeutics segment and building on Senn’s specialised CDMO capabilities, we are well-positioned to deliver high-quality, next-generation treatments. Senn’s specialised expertise in peptide development and its strong customer relationships complement Granules’ manufacturing strength and global reach. Together, we aim to drive meaningful impact in the complex therapeutics space.”
Granules India started in 1991 and, based in Hyderabad, is a fast-growing pharmaceutical company. It handles the full manufacturing process from raw ingredients to finished medicines and serves over 300 customers in more than 80 countries. The company runs 10 factories (8 in India and 2 in the USA) and has approvals from major global health authorities.
As of April 11, 2025, at 11:00 AM, Granules India Limited Share Price is trading at ₹450.35 per share, reflecting a profit of 4.47% from the previous closing price. Over the past month, the stock has registered a loss of 5.92%. The stock’s 52-week high stands at ₹721.00 per share, while its low is ₹389.35 per share.
Senn Chemicals, established in 1963 and based in Switzerland, is well-known for making custom peptides. They support companies in the pharmaceutical, cosmetic and theragnostic fields. They use advanced methods like Liquid-Phase and Solid-Phase Peptide Synthesis and provide services from research to full-scale production.
The deal helps Granules grow in advanced drug development and expand globally. It marks a big step in its journey toward offering next-generation treatments.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Apr 11, 2025, 2:10 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
